• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?

作者信息

Katsiki Niki, Perakakis Nikolaos, Mantzoros Christos

机构信息

Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.

Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.

出版信息

Metabolism. 2019 Sep;98:iii-ix. doi: 10.1016/j.metabol.2019.07.009. Epub 2019 Jul 11.

DOI:10.1016/j.metabol.2019.07.009
PMID:31301336
Abstract
摘要

相似文献

1
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对非酒精性脂肪性肝病/非酒精性脂肪性肝炎的影响：既往与未来？
Metabolism. 2019 Sep;98:iii-ix. doi: 10.1016/j.metabol.2019.07.009. Epub 2019 Jul 11.
2
Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).抑制钠-葡萄糖共转运蛋白 2（SGLT2）可延缓非酒精性脂肪性肝炎（NASH）鱼类模型的肝纤维化。
FEBS Open Bio. 2019 Feb 15;9(4):643-652. doi: 10.1002/2211-5463.12598. eCollection 2019 Apr.
3
Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.达格列净和/或甘精胰岛素对 db/db 小鼠胰岛β细胞质量和肝脂肪变性的影响。
Metabolism. 2019 Sep;98:27-36. doi: 10.1016/j.metabol.2019.06.006. Epub 2019 Jun 14.
4
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.钠-葡萄糖协同转运蛋白2抑制剂达格列净对2型糖尿病合并非酒精性脂肪性肝病患者血清可溶性二肽基肽酶-4水平的影响。
Int J Clin Pract. 2019 May;73(5):e13335. doi: 10.1111/ijcp.13335. Epub 2019 Apr 1.
5
Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.新型 SGLT2 抑制剂 NGI001 延迟干预可抑制小鼠饮食诱导的代谢功能障碍和非酒精性脂肪性肝病。
Br J Pharmacol. 2020 Jan;177(2):239-253. doi: 10.1111/bph.14859. Epub 2019 Nov 12.
6
[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].[无明显高血糖的酸中毒：与SGLT2抑制剂相关的正常血糖性糖尿病酮症酸中毒]
Med Klin Intensivmed Notfmed. 2017 Mar;112(2):145-148. doi: 10.1007/s00063-016-0153-0. Epub 2016 May 24.
7
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的心血管结局临床试验的临床意义。
Atherosclerosis. 2018 May;272:33-40. doi: 10.1016/j.atherosclerosis.2018.03.013. Epub 2018 Mar 8.
8
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.SGLT2 抑制剂：用于治疗 2 型糖尿病和其他慢性病的未来选择。
Diabetologia. 2018 Oct;61(10):2134-2139. doi: 10.1007/s00125-018-4678-z. Epub 2018 Aug 22.
9
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂治疗 2 型糖尿病的药效学、疗效和安全性。
Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265-014-0337-y.
10
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂及其改善2型糖尿病患者血糖水平的机制。
Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819.

引用本文的文献

1
Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis.达格列净治疗2型糖尿病患者非酒精性脂肪性肝病的疗效：一项荟萃分析。
Medicine (Baltimore). 2025 Jan 3;104(1):e40836. doi: 10.1097/MD.0000000000040836.
2
The Cardiac-Kidney-Liver (CKL) syndrome: the "real entity" of type 2 diabetes mellitus.心肾肝（CKL）综合征：2型糖尿病的“真实实体”。
Arch Med Sci. 2024 Jan 31;20(1):207-215. doi: 10.5114/aoms/183070. eCollection 2024.
3
Sotagliflozin attenuates liver-associated disorders in cystic fibrosis rabbits.
索他格列净可减轻囊性纤维化兔的肝脏相关疾病。
JCI Insight. 2024 Feb 15;9(6):e165826. doi: 10.1172/jci.insight.165826.
4
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders.钠-葡萄糖协同转运蛋白2抑制剂在肝脏疾病中的肝脏益处。
EXCLI J. 2023 Apr 21;22:403-414. doi: 10.17179/excli2023-6022. eCollection 2023.
5
Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes.非酒精性脂肪性肝病中降低肝脏脂肪的治疗潜力：与2型糖尿病密切相关
Metabolites. 2023 Apr 4;13(4):517. doi: 10.3390/metabo13040517.
6
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study.恩格列净联合二甲双胍与二甲双胍单药治疗对2型糖尿病患者非酒精性脂肪性肝病进展的影响：IMAGIN初步研究
Biomedicines. 2023 Jan 23;11(2):322. doi: 10.3390/biomedicines11020322.
7
Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.恩格列净改善非糖尿病肥胖非酒精性脂肪性肝炎（NASH）活检证实的小鼠模型的代谢和肝脏结局。
Int J Mol Sci. 2021 Jun 13;22(12):6332. doi: 10.3390/ijms22126332.
8
Treatments for NAFLD: State of Art.非酒精性脂肪性肝病的治疗：现状
Int J Mol Sci. 2021 Feb 26;22(5):2350. doi: 10.3390/ijms22052350.
9
Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway and .恩格列净通过激活AMPK-TET2-自噬途径减轻肝脂肪变性 以及 。 （注：原文结尾似乎不完整，翻译可能会因原文信息缺失存在一定局限性）
Front Pharmacol. 2021 Jan 20;11:622153. doi: 10.3389/fphar.2020.622153. eCollection 2020.
10
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE Mice by Activating Autophagy and Reducing ER Stress and Apoptosis.恩格列净通过激活自噬和减少内质网应激和细胞凋亡减轻高脂饮食喂养的载脂蛋白 E 小鼠的非酒精性脂肪性肝病 (NAFLD)。
Int J Mol Sci. 2021 Jan 15;22(2):818. doi: 10.3390/ijms22020818.